United States Pharmaceuticals

Syros Pharmaceuticals Inc (SYRS)

Track

Ticker: SYRS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Syros Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 14 Mar 2025
Value US$4,492,997.94 | Price 303.04 | Shares 78,561
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-14 2025-03-14 PrS Proposed sale
Fanucci Marsha

Director

Non-Executive Director
78,561
303.04
US$4,492,998 		78,561 303.04 US$4,492,998
2025-03-11 2025-03-11 PrS Proposed sale
0.5
WIRTH PETER

Director

Non-Executive Director
72,169
421.83
US$52,528 		72,169 421.83 US$52,528
2024-12-30 2024-12-30 PrS Proposed sale
3.6
AKKARAJU SRINIVAS

Director

Non-Executive Director
40,031
373.43
US$4,802,780 		40,031 373.43 US$4,802,780
2025-01-16 2024-12-27 PrS Proposed sale
Flagship Pioneering Fund VII, L.P.

Affiliate
1,135,308
0.24
US$272,474 		1,135,308 0.24 US$272,474
2024-12-27 2024-12-27 PrS Proposed sale
Flagship Pioneering Fund VII, L.P.

Affiliate
1,331,624
0.21
US$279,641 		1,331,624 0.21 US$279,641
2024-12-13 2024-12-13 PrS Proposed sale
Flagship VentureLabs IV LLC

Affiliate
21,333
0.23
US$4,907 		21,333 0.23 US$4,907
2024-12-13 2024-12-13 PrS Proposed sale
Flagship Pioneering Fund VII, L.P.

Affiliate
1,000,000
0.23
US$230,000 		1,000,000 0.23 US$230,000
2024-12-13 2024-12-13 PrS Proposed sale
Flagship Ventures Fund IV-RX, LP

Affiliate
55,925
0.23
US$12,863 		55,925 0.23 US$12,863
2024-12-13 2024-12-13 PrS Proposed sale
Flagship Ventures Fund IV, LP

Affiliate
216,590
0.23
US$49,816 		216,590 0.23 US$49,816
2024-12-10 2024-12-10 PrS Proposed sale
Richard Young

Director

Non-Executive Director
6,667
0.23
US$1,533 		6,667 0.23 US$1,533
2024-12-04 2024-12-02 S Sale
3.7
Simonian Nancy A
Non-Executive Director
37,070 -90.3%
0.27
US$10,016 		37,070 -90.3% 0.27 US$10,016
2024-12-02 2024-12-02 PrS Proposed sale
3.7
Nancy Cole

Director

Non-Executive Director
37,070
0.27
US$10,016 		37,070 0.27 US$10,016
2024-11-27 2024-11-25 S Sale
3.7
Simonian Nancy A
Non-Executive Director
134,713 -76.6%
0.27
US$35,739 		134,713 -76.6% 0.27 US$35,739
2024-11-25 2024-11-25 PrS Proposed sale
3.7
Simonian Nancy A

Director

Non-Executive Director
134,713
0.20
US$26,943 		134,713 0.20 US$26,943
2024-11-20 2024-11-19 S Sale
3.1
Quirk Gerald E

Chief Legal & Compliance Offic

Officer
46,657 -100.0%
0.22
US$10,321 		46,657 -100.0% 0.22 US$10,321
2024-11-19 2024-11-19 PrS Proposed sale
3.1
Quirk Gerald E

Officer

Officer
46,657
0.22
US$10,323 		46,657 0.22 US$10,323
2024-11-20 2024-11-18 S Sale
1.3
Chee Conley

President & CEO

Executive Director
134,797 -100.0%
0.20
US$26,932 		134,797 -100.0% 0.20 US$26,932
2024-11-20 2024-11-18 S Sale
2.2
Roth David

Chief Medical Officer

Officer
12,099 -100.0%
0.20
US$2,382 		12,099 -100.0% 0.20 US$2,382
2024-11-20 2024-11-18 S Sale
3.1
Stephens Kristin

Chief Development Officer

Officer
36,133 -100.0%
0.22
US$7,949 		36,133 -100.0% 0.22 US$7,949
2024-11-20 2024-11-18 S Sale
1.1
Haas Jason

Chief Financial Officer

Officer
137,803 -100.0%
0.21
US$28,980 		137,803 -100.0% 0.21 US$28,980
2024-11-18 2024-11-18 PrS Proposed sale
1.1
Haas Jason

Officer

Officer
37,803
0.23
US$8,669 		37,803 0.23 US$8,669
2024-11-18 2024-11-18 PrS Proposed sale
2.2
Roth David

Officer

Officer
12,099
0.20
US$2,382 		12,099 0.20 US$2,382
2024-11-18 2024-11-18 PrS Proposed sale
3.1
Stephens Kristin

Officer

Officer
36,133
0.22
US$7,949 		36,133 0.22 US$7,949
2024-11-18 2024-11-18 PrS Proposed sale
1.3
Chee Conley

Officer

Officer
30,797
0.20
US$6,139 		30,797 0.20 US$6,139
2024-11-18 2024-11-18 PrS Proposed sale
1.3
Chee Conley

Officer

Officer
100,000
0.26
US$25,930 		100,000 0.26 US$25,930
2024-11-18 2024-11-18 PrS Proposed sale
1.1
JASON HAAS

Officer; Director

Executive Director
100,000
0.20
US$20,310 		100,000 0.20 US$20,310
2024-09-12 2024-09-12 B Purchase
1.1
Haas Jason

Chief Financial Officer

Officer
45,344 +57.2%
1.68
US$76,006 		45,344 +57.2% 1.68 US$76,006
2024-09-12 2024-09-11 B Purchase
1.1
Haas Jason

Chief Financial Officer

Officer
19,293 +32.2%
1.58
US$30,446 		19,293 +32.2% 1.58 US$30,446
2024-09-12 2024-09-11 B Purchase
1.3
Chee Conley

President & CEO

Executive Director
50,000 +69.0%
1.71
US$85,420 		50,000 +69.0% 1.71 US$85,420
2024-09-12 2024-09-10 B Purchase
1.1
Haas Jason

Chief Financial Officer

Officer
35,363 +144.0%
1.55
US$54,788 		35,363 +144.0% 1.55 US$54,788
2024-09-12 2024-09-10 B Purchase
1.3
Chee Conley

President & CEO

Executive Director
50,000 +222.2%
1.51
US$75,260 		50,000 +222.2% 1.51 US$75,260
2024-07-02 2024-06-28 PlS Planned sale
Young Richard A
Non-Executive Director
34,837 -81.3%
5.12
US$178,365 		34,837 -81.3% 5.12 US$178,365
2024-06-28 2024-06-28 PrS Proposed sale
Young Richard A

Director

Non-Executive Director
34,837
5.72
US$199,268 		34,837 5.72 US$199,268
2024-04-05 2024-04-03 PlS Planned sale
2.2
Roth David

Chief Medical Officer

Officer
10,451 -100.0%
4.95
US$51,732 		10,451 -100.0% 4.95 US$51,732
2024-04-03 2024-04-03 PrS Proposed sale
2.2
Roth David

Officer

Officer
10,451
4.95
US$51,732 		10,451 4.95 US$51,732
2024-04-02 2024-04-02 PrS Proposed sale
2.2
Roth David

Officer

Officer
150
4.98
US$747 		150 4.98 US$747
2024-04-02 2024-04-02 PlS Planned sale
2.2
Roth David

Chief Medical Officer

Officer
150 -1.4%
4.98
US$747 		150 -1.4% 4.98 US$747
2023-12-26 2023-12-21 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
904,977 +102.7%
4.42
US$3,999,998 		904,977 +102.7% 4.42 US$3,999,998
2023-12-14 2023-12-12 PlS Planned sale
2.2
Roth David

Chief Medical Officer

Officer
6,287 -100.0%
4.95
US$31,121 		6,287 -100.0% 4.95 US$31,121
2023-12-12 2023-12-12 PrS Proposed sale
2.2
Roth David

Officer

Officer
6,287
4.95
US$31,121 		6,287 4.95 US$31,121
2023-12-08 2023-12-06 PlS Planned sale
2.2
Roth David

Chief Medical Officer

Officer
6,287 -50.0%
3.95
US$24,834 		6,287 -50.0% 3.95 US$24,834
2023-12-06 2023-12-06 PrS Proposed sale
2.2
Roth David

Officer

Officer
6,287
3.95
US$24,834 		6,287 3.95 US$24,834
2023-08-02 2023-07-31 PlS Planned sale
2.2
Roth David

Chief Medical Officer

Officer
7,348 -100.0%
3.95
US$29,025 		7,348 -100.0% 3.95 US$29,025
2023-07-31 2023-07-31 PrS Proposed sale
2.2
Roth David

Officer; Chief Medical Officer

Officer
7,348
3.95
US$29,025 		7,348 3.95 US$29,025
2023-07-18 2023-07-17 PlS Planned sale
2.4
Olson Eric R

Chief Scientific Officer

Officer
689 -9.4%
3.50
US$2,412 		689 -9.4% 3.50 US$2,412
2023-07-17 2023-07-17 PrS Proposed sale
2.4
Olson Eric R

Officer

Officer
689
3.50
US$2,412 		689 3.50 US$2,412
2022-10-03 2022-09-30 B Purchase
0.9
TYSON TIMOTHY
Non-Executive Director
14,000 +128.1%
6.37
US$89,186 		14,000 +128.1% 6.37 US$89,186
2022-10-03 2022-09-29 B Purchase
0.9
TYSON TIMOTHY
Non-Executive Director
2,932 +36.6%
5.72
US$16,770 		2,932 +36.6% 5.72 US$16,770
2022-01-06 2022-01-05 PlS Planned sale
2.4
Olson Eric R

Chief Scientific Officer

Officer
2,208 -100.0%
3.47
US$7,655 		2,208 -100.0% 3.47 US$7,655
2021-03-17 2021-03-15 PlS Planned sale
2.4
Olson Eric R

Chief Scientific Officer

Officer
3,628 -100.0%
9.47
US$34,372 		3,628 -100.0% 9.47 US$34,372
2021-02-18 2021-02-16 PlS Planned sale
Young Richard A
Non-Executive Director
3,750 -1.2%
12.05
US$45,188 		3,750 -1.2% 12.05 US$45,188
2021-02-10 2021-02-08 PlS Planned sale
Young Richard A
Non-Executive Director
3,750 -1.1%
13.04
US$48,900 		3,750 -1.1% 13.04 US$48,900
2020-11-18 2020-11-17 PlS Planned sale
Young Richard A
Non-Executive Director
5,357 -1.6%
8.75
US$46,874 		5,357 -1.6% 8.75 US$46,874
2020-11-18 2020-11-16 PlS Planned sale
Young Richard A
Non-Executive Director
633 -0.2%
8.98
US$5,684 		633 -0.2% 8.98 US$5,684
2020-10-19 2020-10-19 PlS Planned sale
Young Richard A
Non-Executive Director
5,673 -1.7%
8.75
US$49,639 		5,673 -1.7% 8.75 US$49,639
2020-10-16 2020-10-15 PlS Planned sale
Young Richard A
Non-Executive Director
317 -0.1%
8.75
US$2,774 		317 -0.1% 8.75 US$2,774
2020-09-16 2020-09-15 PlS Planned sale
Young Richard A
Non-Executive Director
5,990 -1.7%
10.39
US$62,236 		5,990 -1.7% 10.39 US$62,236
2020-08-19 2020-08-18 PlS Planned sale
2.4
Olson Eric R

Chief Scientific Officer

Officer
10,787 -100.0%
13.00
US$140,231 		10,787 -100.0% 13.00 US$140,231
2020-08-19 2020-08-18 PlS Planned sale
3.6
AKKARAJU SRINIVAS
Non-Executive Director
158,583 -11.1%
13.10
US$2,076,724 		158,583 -11.1% 13.10 US$2,076,724
2020-08-19 2020-08-17 PlS Planned sale
2.4
Olson Eric R

Chief Scientific Officer

Officer
4,963 -100.0%
13.00
US$64,519 		4,963 -100.0% 13.00 US$64,519
2020-08-19 2020-08-17 PlS Planned sale
3.6
AKKARAJU SRINIVAS
Non-Executive Director
744 -0.1%
13.00
US$9,672 		744 -0.1% 13.00 US$9,672
2020-08-19 2020-08-17 PlS Planned sale
Young Richard A
Non-Executive Director
5,990 -1.7%
12.59
US$75,414 		5,990 -1.7% 12.59 US$75,414
2020-07-17 2020-07-15 PlS Planned sale
Young Richard A
Non-Executive Director
5,990 -1.7%
11.85
US$70,982 		5,990 -1.7% 11.85 US$70,982
2020-07-07 2020-07-07 PlS Planned sale
2.4
Olson Eric R

Chief Scientific Officer

Officer
1,753 -100.0%
11.72
US$20,538 		1,753 -100.0% 11.72 US$20,538
2020-07-06 2020-07-01 PlS Planned sale
3.6
AKKARAJU SRINIVAS
Non-Executive Director
4,627 -0.3%
11.01
US$50,966 		4,627 -0.3% 11.01 US$50,966
2020-06-25 2020-06-25 PlS Planned sale
3.6
AKKARAJU SRINIVAS
Non-Executive Director
54,972 -3.7%
11.15
US$612,850 		54,972 -3.7% 11.15 US$612,850
2020-06-25 2020-06-24 PlS Planned sale
3.6
AKKARAJU SRINIVAS
Non-Executive Director
48,775 -3.2%
11.07
US$539,788 		48,775 -3.2% 11.07 US$539,788
2020-06-25 2020-06-23 PlS Planned sale
3.6
AKKARAJU SRINIVAS
Non-Executive Director
50,953 -3.2%
11.11
US$565,930 		50,953 -3.2% 11.11 US$565,930
2020-06-16 2020-06-15 PlS Planned sale
Young Richard A
Non-Executive Director
5,990 -1.6%
8.75
US$52,412 		5,990 -1.6% 8.75 US$52,412
2020-05-15 2020-05-15 PlS Planned sale
Young Richard A
Non-Executive Director
5,990 -1.6%
9.22
US$55,242 		5,990 -1.6% 9.22 US$55,242
2020-05-13 2020-05-13 B Purchase
3.4
Alles Mark J
Non-Executive Director
10,000 +inf%
8.86
US$88,590 		10,000 +inf% 8.86 US$88,590
2020-04-17 2020-04-15 PlS Planned sale
Young Richard A
Non-Executive Director
23,960 -6.1%
8.75
US$209,650 		23,960 -6.1% 8.75 US$209,650
2020-02-20 2020-02-18 PlS Planned sale
2.4
Olson Eric R

Chief Scientific Officer

Officer
1,446 -100.0%
7.38
US$10,674 		1,446 -100.0% 7.38 US$10,674
2019-11-12 2019-11-12 PP Planned purchase Springhorn Jeremy P.

Chief Business Officer

Officer
10,121 +40.7%
4.97
US$50,268 		10,121 +40.7% 4.97 US$50,268
2019-11-12 2019-11-11 PP Planned purchase Springhorn Jeremy P.

Chief Business Officer

Officer
9,879 +65.9%
4.99
US$49,328 		9,879 +65.9% 4.99 US$49,328
Explore more

More insider trading research around Syros Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America